Greifswald Hansestadt, Germany

  • Featured

    Flexible-Dose Trial in Early Parkinson's Disease (PD)

    Phase

    3

    Span

    256 weeks

    Sponsor

    Cerevel Therapeutics, LLC

    Strasbourg

    Recruiting

  • Featured

    TemPo Studies

    **All eligible study participants will receive at no cost:** • Study-related consultation and care • Study visits, tests, assessments, and procedures • Study drugs (investigational drug or placebo)

    Phase

    N/A

    Span

    212 weeks

    Sponsor

    Cerevel Therapeutics

    Strasbourg

    Recruiting

  • Featured

    A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

    For more information, please contact Incyte Corporation at 1.855.463.3463 or visit **[www.incyteclinicaltrials.com](https://www.incyteclinicaltrials.com/)**

    Phase

    2

    Span

    Sponsor

    Strasbourg

    Recruiting

  • Featured

    Study to evaluate HZN-825 in patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

    This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial for HZN-825, a selective antagonist of lysophosphatidic acid receptor-1 (LPAR1). Participants will be screened within 4 weeks prior to the Baseline (Day 1) Visit. Approximately 300 participants who meet the trial eligibility criteria will be randomized on Day 1 in a 1:1:1 ratio to receive HZN-825 300 mg QD, HZN-825 300 mg BID or placebo for 52 weeks. Participants will take their first dose of trial drug at the clinic and will return to the clinic for trial visits at Week 4 and every 6 weeks thereafter until Week 52. Participants who complete the Double-blind Treatment Period (Week 52) may be eligible to enter a 52-week extension trial (HZNP- HZN-825-302). Participants not entering the extension will return to the clinic for a Safety Follow-up Visit 4 weeks after the last dose of trial drug.

    Phase

    2

    Span

    139 weeks

    Sponsor

    Horizon Therapeutics Ireland DAC

    Strasbourg

    Recruiting

  • Featured

    A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

    Phase

    2

    Span

    Sponsor

    Strasbourg, Strasbourg

    Recruiting

  • Cauterization of the Anterior Ethmoidal Artery by Transconjunctival Approach

    The objective of the study was to compare the efficacy of transconjunctival and external cauterization of the anterior ethmoidal artery in patients with refractory epistaxis

    Phase

    N/A

    Span

    53 weeks

    Sponsor

    University Hospital, Strasbourg, France

    Strasbourg

    Recruiting

  • Inventory of the Management of Acute Community-acquired Pneumonia in Strasbourg University Hospitals

    The objective of the study is to determine the epidemiological, clinical, biological and imaging characteristics of people admitted for acute community-acquired pneumonia.

    Phase

    N/A

    Span

    131 weeks

    Sponsor

    University Hospital, Strasbourg, France

    Strasbourg

    Recruiting

  • Impact of the Development of Pediatric Palliative Care

    The main objective of the study is to compare the occurrence and management of end-of-life symptoms in children who died of a primary brain tumor over 2 periods, in 2009 - 2010 and in 2019 - 2020, followed in the Pediatric Oncology departments of Strasbourg, Besançon, Dijon, Nancy and Reims.

    Phase

    N/A

    Span

    150 weeks

    Sponsor

    University Hospital, Strasbourg, France

    Strasbourg

    Recruiting

  • Radiographic Changes and Clinical Implications of Implantation of Shortened Uncemented Femoral Stems in THA

    The objective of this study is to observe the appearance of shortened stem radiological abnormalities at least 2 years postoperatively.

    Phase

    N/A

    Span

    64 weeks

    Sponsor

    University Hospital, Strasbourg, France

    Strasbourg

    Recruiting

  • REVErsing Airway Remodelling With Tezepelumab

    Tezepelumab is a human IgG2l monoclonal antibody (mAb) directed against TSLP. Double-blind, randomized controlled trials comparing Tezepelumab treatment against placebo demonstrate net positive benefits in asthma patients. Animal research currently indicates that blocking TSLP can prevent bronchial remodelling in murine models (Chen et al. 2013), but no such observations have been attempted in humans. Within this context, the aim of this protocol is to perform a first randomized controlled trial evaluating how Tezepelumab affects the bronchial morphology (and computed tomographic variables in general) of asthmatic patients. In parallel, the investigators also hope to reproduce clinical benefits and perform a transcriptomic study that will juxtapose changes in genetic expression with changes in bronchial morphology and inflammatory signatures. The general hypothesis is that tezepelumab treatment is capable of at least partially reversing bronchial remodelling as detected on computed-tomographic (CT) scans. The investigators also expect such reversal to occur within a unique physiological repair environment that will be reflected by transcriptomic profiles. The primary objective of this protocol is therefore to compare the change-from-baseline in the average percentage bronchial wall area (%WA = (wall area (mm2)/ (wall area (mm2) + lumen area (mm2)))×100) for patients with asthma and undergoing 6 months of tezepelumab treatment with a similar population treated via placebo. Secondarily, continued treatment effects associated with longer treatment (12 months) or remanence after treatment stopping at 6 months will also be quantified. Study arms will additionally be compared in terms of: - Changes in radiomics (CT-scan data); - Changes in exacerbation rates and lung function; - Changes in serum club cell secretory protein (CCSP); - Changes in nasal single-cell transcriptomic signatures. This study also has an exploratory component designed to characterize the physiological repair environment. In depth radiomic and transcriptomic (including single-cell analyses) profiling will be performed. Finally, the capacity of baseline data to predict the response to tezepelumab will also be explored.

    Phase

    3

    Span

    166 weeks

    Sponsor

    University Hospital, Montpellier

    Strasbourg

    Recruiting

1-10 of 839